De Leval, X., Hanson, J., David, J.-L., Masereel, B., Pirotte, B., & Dogné, J.-M. (2004). New developments on thromboxane and prostacyclin modulators. Part II: prostacyclin modulators. Current Medicinal Chemistry, 11, 1243-1252. doi:10.2174/0929867043365279 |
Hanson, J., De Leval, X., David, J.-L., Supuran, C., Pirotte, B., & Dogné, J.-M. (2004). Progress in the field of GPIIb/IIIa antagonists. Current Medicinal Chemistry - Cardiovascular and Hematological Agents, 2, 157-167. doi:10.2174/1568016043477224 |
de Leval, X. J., Dassesse, T., Benoit, V., Pirotte, B., Merville, M.-P., David, J.-L., Castronovo, V., & Dogné, J.-M. (16 November 2003). Pharmacological evaluation of BM-573, a dual thromboxane A(2) receptor antagonist and thromboxane synthase inhibitor, as potential anti-metastatic agent. Blood, 102 (11, Part 2), 72. |
De Leval, X., Dassesse, T., Benoit, V., Pirotte, B., David, J.-L., Merville, M.-P., Castronovo, V., & Dogné, J.-M. (2003). Pharmacological evaluation of BM-573, a dual thromboxane A2 receptor antagonist and thromboxane synthase inhibitor, as potential anti-metastatic agent. Blood, 72. |
Dogné, J.-M., de Leval, X., Kolh, P., Sanna, V., Rolin, S., Michaux, C., Mauer, M., David, J.-L., Masereel, B., & Pirotte, B. (January 2003). Pharmacological evaluation of the novel thromboxane modulator BM-567 (I/II). Effects of BM-567 on platelet function. Prostaglandins, Leukotrienes, and Essential Fatty Acids, 68 (1), 49-54. doi:10.1016/S0952-3278(02)00236-3 |
Barthelemy, N., David, J.-L., Bosquee, L., Bury, T., Seidel, L., Albert, A., Bartsch, P., BAUGNET-MAHIEU, L., & Deneufbourg, J.-M. (March 2002). Increased TGFβ1 plasma level in patients with lung cancer: potential mechanisms. European Journal of Clinical Investigation, 32 (3), 193-198. doi:10.1046/j.1365-2362.2002.00956.x |
De Leval, X., Benoit, V., Neven, P., Benoit, P., Michaux, C., Masereel, B., Pirotte, B., David, J.-L., & Dogné, J.-M. (2002). Effects of thromboxane A2 receptor antagonists and thromboxane synthase inhibitors on osteogenic sarcoma cell-induced platelet aggregation. Fundamental and Clinical Pharmacology, 16, 245. |
de Leval, X., David, J.-L., Neven, P., Benoit, V., Pirotte, B., Merville, M.-P., Bours, V., & Dogné, J.-M. (16 November 2001). Effects of BM-573, a dual thromboxane A(2) receptor antagonist and thromboxane synthase inhibitor, on osteogenic sarcoma cell-induced platelet aggregation. Blood, 98 (11, Part 2), 43. |
Fumal, A., Belachew, S., Moonen, G., & David, J.-L. (July 2001). Le cas clinique du mois. A propos d'un cas de syndrome des antiphospholipides. Revue Médicale de Liège, 56 (7), 480-3. |
Letawe-Gilis, L., Lambermont, B., & David, J.-L. (July 2001). Accidents thrombo-emboliques veineux et arteriels chez un patient porteur d'une mutation du facteur V R506Q Leiden et ayant developpe une reaction immuno-allergique a l'heparine. Revue Médicale de Liège, 56 (7), 493-6. |
Dogné, J. M., Rolin, S., de Leval, X., Benoit, P., Neven, P., Delarge, J., Kolh, P., Damas, J., David, J.-L., & Masereel, B. (2001). Pharmacology of the Thromboxane Receptor Antagonist and Thromboxane Synthase Inhibitor Bm-531. Cardiovascular Drug Reviews, 19 (2, Summer), 87-96. doi:10.1111/j.1527-3466.2001.tb00057.x |
Defraigne, J.-O., Pincemail, J., Dekoster, G., Larbuisson, R., Dujardin, M., Blaffart, F., David, J.-L., & Limet, R. (December 2000). Sma Circuits Reduce Platelet Consumption and Platelet Factor Release During Cardiac Surgery. Annals of Thoracic Surgery, 70 (6), 2075-81. doi:10.1016/S0003-4975(00)01838-5 |
David, J.-L., & Limet, R. (November 1999). Antiplatelet Activity of Clopidogrel in Coronary Artery Bypass Graft Surgery Patients. Thrombosis and Haemostasis, 82 (5), 1417-21. doi:10.1055/s-0037-1614847 |
Gougnard, T., Charlier, C., David, J.-L., & Plomteux, G. (1999). Concentrations plasmatiques de la vitamine K1 et de l'acenocoumarol en fonction du temps de quick (I.N.R.). Acta Clinica Belgica. Supplementum, S1, 32-4. |
VAN DAMME, H., DAVID, J.-L., & Limet, R. (1999). Les agents antiplaquettaires en chirurgie vasculaire périphérique. Revue Médicale de Liège, 54 (2), 109-17. |
Bastos da Silva, M., Dessy, C., Coghe, J., David, J.-L., & Lekeux, P. (1998). Protective Effects of Web 2086 (Paf Antagonist) and Ketoprofen (Nsaid) on Paf-Induced Changes in the Morphological Ultrastructure of Blood Platelets in Calves. Veterinary Research Communications, 22 (4), 273-291. doi:10.1023/A:1006007802126 |
Bastos da Silva, M., Gustin, P., Herion, F., David, J.-L., Van de Weerdt, M., & Lekeux, P. (1998). Effect of Ketoprofen on Paf-Induced Bovine Platelet Aggregation. Veterinary Journal, 155 (2), 201-203. doi:10.1016/S1090-0233(98)80020-8 |
Bastos da Silva, M., Dessy, C., David, J.-L., & Lekeux, P. (1997). Morphological alterations of blood platelets induced by Platelet Activating Factor (PAF) and partial inhibition by Ketoprofen in calves. Veterinary Research, 28 (5 Sep-Oct), 489-502. |
Bastos da Silva, M., Gustin, P., Herion, F., Raskinet, R., David, J.-L., Gougnard, T., Plomteux, G., Desmecht, D., & Lekeux, P. (1997). The Effect of Intravenous Administration of Web 2086 on Paf-Induced Platelet Aggregation in Healthy Friesian Calves. Veterinary Research Communications, 21 (7), 521-531. doi:10.1023/A:1005950622207 |
Bastos da Silva, M., Herion, F., Raskinet, R., David, J.-L., Gustin, P., & Lekeux, P. (1997). Combined Effect of Web 2086 (Paf Antagonist) and Ketoprofen (Nsaid) on Paf-Induced Ex Vivo Platelet Aggregation in Bovine. Journal of Veterinary Medicine. A, Physiology, Pathology, Clinical Medicine, 44 (2), 65-71. doi:10.1111/j.1439-0442.1997.tb01087.x |
Janssens, M., Hartstein, G., & David, J.-L. (December 1996). Reduction in Requirements for Allogeneic Blood Products: Pharmacologic Methods. Annals of Thoracic Surgery, 62 (6), 1944-50. doi:10.1016/S0003-4975(96)00940-X |
Bastos da Silva, M., Herion, F., Raskinet, R., David, J.-L., Gustin, P., Dessy, C., & Lekeux, P. (1996). Inhibition of Paf-Induced Platelet Aggregation by Web 2086 'in-Vitro', an Antagonist to the Receptor for Platelet-Activating Factor, in Bovine. Journal of Veterinary Medicine. A, Physiology, Pathology, Clinical Medicine, 43 (7), 399-413. doi:10.1111/j.1439-0442.1996.tb00468.x |
Janssens, M., Joris, J., David, J.-L., Lemaire, R., & Lamy, M. (1994). High-dose aprotinin reduces blood loss in patients undergoing total hip replacement surgery. Anesthesiology, 80, 23-29. doi:10.1097/00000542-199401000-00007 |
Van Damme, H., Damas, P., David, J.-L., & Limet, R. (December 1990). Heparin-induced thrombocytopenia: A case report. Angiology, 41 (12), 1075-1081. doi:10.1177/000331979004101209 |
David, J.-L., GASPARD, U., Gillain, D., Raskinet, R., & Lepot, M. R. (July 1990). Hemostasis Profile in Women Taking Low-Dose Oral Contraceptives. American Journal of Obstetrics and Gynecology, 163 (1, Pt 2), 420-3. doi:10.1016/0002-9378(90)90594-W |
Limet, R., David, J.-L., Magotteaux, P., Larock, M. P., & Rigo, P. (November 1987). Prevention of Aorta-Coronary Bypass Graft Occlusion. Beneficial Effect of Ticlopidine on Early and Late Patency Rates of Venous Coronary Bypass Grafts: A Double-Blind Study. Journal of Thoracic and Cardiovascular Surgery, 94 (5), 773-83. doi:10.1016/s0022-5223(19)36194-x |
Andrien, F., Lemaire, M., Beguin, Y., Bury, J., Closon, J., David, J.-L., Dejardin-Closon, M.-T., Duvivier, A., Fillet, G., & Tjean, M. (1986). Second tumors and myeloproliferative diseases after Hodgkin's disease treatment. Leukemia Research, 10, 887. |